New combo therapy before surgery shows promise for rare skin cancer
NCT ID NCT05594290
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide before their planned surgery. The main goal is to see how many patients have no cancer left in the removed tissue.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MERKEL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Milan, 20133, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a lighter immunotherapy schedule keep advanced cancers in check?
- Blood markers could spot hidden skin cancer return
- Cancer-Killing virus shows promise in early trial for advanced tumors
- Immune cell therapy shows promise for tough cancers
- New database aims to crack the code on three rare skin cancers
- New scan could spot hidden tumors more accurately